Menu
  • Join
  • Login
  • Contact
 

Search abstracts


New Delivery Systems for Intranasal Lipopeptide-based Vaccine against Group A Streptococcus

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Presentation
  • By: SKWARCYNZKSI, Mariusz (Brisbane, Australia)
  • Co-author(s): Mariusz Skwarczynski: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia
    Nirmal Marasini: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia
    Khairunnisa Abdul Ghaffar: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia
    Ashwini Kumar Giddam: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia
    Michael R. Batzloff: Institute for Glycomics, Griffith University, Gold Coast, Australia
    Michael F. Good: Institute for Glycomics, Griffith University, Gold Coast, Australia
    Istvan Toth: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Australia;Pharmacy Australia Centre of Excellence, The University of Queensland, Woolloongabba, Australia;Institute for Molecular Bioscience, The University of Queensland, St Lucia, Australia
  • Abstract:

    Backgrounds

    An intranasal delivery of vaccines is one of the most preferable routes of administration. Induction of mucosal immunity by Group A streptococcus (GAS) vaccine is highly preferable as the first step of GAS infection is typically following throat (mucosal) colonization. 

    Aims

    The purpose of this study was to develop intranasal

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses